groupH asked senior EU payers to comment on how they assess Value in Rare Diseases and how it is different from more prevalent indications. Click below to watch one of the interviews, with Bruno Falissard. Bruno is a former member of the Transparency Commission at HAS, Psychiatrist and Biostatistician, and Head of Research Unit Inserm […]
About Kate Bankhead
This author has yet to write their bio.Meanwhile lets just say that we are proud Kate Bankhead contributed a whooping 13 entries.
Entries by Kate Bankhead
groupH explored the different approaches and philosophies behind Market Research and Consulting from the perspective of individuals with a Market Research, Strategy Consulting and Pharma background through a short online survey. Please find the results and insights and a graphic showing how the MR and Consulting value chain, capabilities, project types and underlying value driving […]
groupH was selected to present on the topic of Looking for and Quantifying Value in Rare Diseases at an EphMRA meeting in Basel on 6th November, 2018. Rare diseases present a number of challenges for manufacturers, which are absent in more prevalent conditions. So which approach should you take when trying to determine value? In his […]
groupH London capturing the late summer sunshine for its annual picnic. This time, for the first time, on Richmond Green in Surrey.
The forecasting role and forecasting tools as part of a corporate business function, or as part of a commercial consulting project in Pharma, Biotech and Medical Device organisations, continue to evolve. Erik Holzinger (groupH) together with Ben Collins (Boehringer Ingelheim) hosted a round-table discussion during this year’s annual EphMRA 2018 Conference in Basel, during June […]
The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mechanisms to improve affordability of such therapies, including ‘affordability thresholds’, price volume agreements or caps on individual […]
The role of forecasting as a business function, or if used as a tool in and outside of Pharma / Device organisations, continues to evolve at a fast pace. Ben Collins (Boehringer Ingelheim) and Erik Holzinger (groupH) are hosting a round-table discussion during this year’s annual EphMRA 2018 Conference in Basel, to open up a […]
As we’re sure you are aware, the biggest healthcare investing event of the year, the JP Morgan Healthcare Conference, will be returning to San Francisco in early January. groupH will be attending the Biotech Showcase – navigating the packed agenda of company presentations, panel discussions, and networking receptions. If you’re in San Francisco for these […]
Longing for time to browse through a book like ‘The Little Prince’ after a hectic December inspired this year’s End-of-Year card drawing by our London based designer, Yasmin El Saie. One line in the book reads: ‘Grown-ups never understand anything on their own, and it’s a nuisance for children to have to keep explaining things […]
This new two-day conference allowed for honest discussions in small groups helped by the simple set-up and high-quality contributions from both payers and industry. Our head of market access, Nicolas Touchot chaired a keynote panel on Preferred Payment Models for cell and gene therapies. The news of Kite’s CAR-T US approval coming in at $373,000 […]